
Daphne Teo
Asia, Singapore'/%3e%3cuse xlink:href='%23a' transform='translate(288.889 -214.211)'/%3e%3cuse xlink:href='%23a' transform='translate(108 342.749)'/%3e%3cuse xlink:href='%23a' transform='translate(469.189 342.749)'/%3e%3c/svg%3e)
Description
Daphne Teo is the CEO and founder of NSG BioLabs.
Investor Profile
Daphne Teo has backed more than 1 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 1 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series C rounds (top funding stages).
- Majority of deals are located in United States.
- Strong thematic focus on Biotechnology, Health Care, Therapeutics.
Stage Focus
- Series C (100%)
Country Focus
- United States (100%)
Industry Focus
- Biotechnology
- Health Care
- Therapeutics
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.